MedTrace Logo

The Effect of Lactobacillus Reuteri Probiotic as an Adjunct Treatment for Helicobacter Pylori Infection in Adults

NCT05399862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-06-01

No results posted yet for this study

Summary

This is a prospective, randomised, double-blind, placebo-controlled trial involving newly diagnosed Helicobacter pylori (H. pylori) patients. Patients will be prescribed with standard triple therapy for 2 weeks and supplemented with either probiotic (Lactobacillus reuteri DSM 17648) or placebo for 4 weeks. In this study, we are investigating the effect of Lactobacillus reuteri in H. pylori eradication; mainly in improving eradication rate, ameliorating gastrointestinal symptoms and reducing adverse effects of antibiotics. We hypothesised that in H. pylori patients receiving Lactobacillus reuteri as adjunct treatment, there will be an improvement in H. pylori eradication rate as well as reduction of gastrointestinal symptoms and treatment adverse effects.

Conditions

  • Helicobacter Pylori Infection

Interventions

DIETARY_SUPPLEMENT

Lactobacillus reuteri DSM 17648 probiotic

Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection

OTHER

Placebo

Placebo capsule with no microbial cell preparation

Sponsors & Collaborators

  • Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia

    collaborator UNKNOWN

  • Universiti Kebangsaan Malaysia Medical Centre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-24
Primary Completion
2021-12-23
Completion
2022-01-10

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399862 on ClinicalTrials.gov